Blockade of Myeloid Suppressor Cells Overcomes the Anti-PD-1/PD-L1 Resistance in KRAS-Driven and LKB1-Deficient NSCLC

被引：0
|
作者：
Li, R. [1 ]
Salehi-Rad, R. [1 ]
Momcilovic, M. [1 ]
Lim, R. [1 ]
Ong, S. [1 ]
Huang, Z. [1 ]
Tran, L. [1 ]
Zhe, J. [1 ]
Paul, M. [1 ]
Teitell, M. [1 ]
Minna, J. [2 ]
Krysan, K. [1 ]
Shackelford, D. [1 ]
Liu, B. [1 ]
Dubinett, S. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] UTSW, Dallas, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A11
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [31] Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1
    Bouchard, N.
    Gauthier, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S462 - S462
  • [32] Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
    Yang, Zhen
    Liu, Xinpeng
    Zhu, Jun
    Chai, Yangyang
    Cong, Boyi
    Li, Bo
    Gao, Wanfeng
    Hu, Ye
    Wen, Mingyue
    Liu, Yanfang
    Fu, Li
    Cao, Xuetao
    CANCER CELL, 2025, 43 (01) : 86 - +
  • [33] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    Patrinely, James Randall, Jr.
    Dewan, Anna K.
    Johnson, Douglas B.
    BIODRUGS, 2020, 34 (04) : 495 - 503
  • [34] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    James Randall Patrinely
    Anna K. Dewan
    Douglas B. Johnson
    BioDrugs, 2020, 34 : 495 - 503
  • [35] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
  • [36] Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
    Shah, Shalin
    Wood, Kevin
    Brisson, Ryan
    Karrison, Theodore
    Hensing, Thomas
    Luke, Jason J.
    Patel, Jyoti D.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S310 - S310
  • [37] In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies
    Denis, Morgane
    Grasselly, Chloe
    Choffour, Pierre-Antoine
    Wierinckx, Anne
    Mathe, Doriane
    Chettab, Kamel
    Tourette, Anne
    Talhi, Nolan
    Bourguignon, Aurore
    Birzele, Fabian
    Kress, Elsa
    Jordheim, Lars Petter
    Klein, Christian
    Matera, Eva-Laure
    Dumontet, Charles
    CANCER IMMUNOLOGY RESEARCH, 2022, 10 (08) : 1013 - 1027
  • [38] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    DRUGS, 2016, 76 (09) : 925 - 945
  • [39] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    Drugs, 2016, 76 : 925 - 945
  • [40] NOVEL APPROACHES TO ADDRESS RESISTANCE TO ANTI PD-1/PD-L1 THERAPY IN NSCLC
    Sehgal, M.
    Das, N.
    Thekkadath, R.
    Mittal, N.
    Chauhan, U.
    Eswaran, S.
    VALUE IN HEALTH, 2019, 22 : S444 - S444
12345